Belite Bio, Inc
BLTE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001889109
In the last 90 days, Belite Bio, Inc insiders filed 0 open-market purchases and 4 sales; 80 institutions reported holding it in 13F filings for Q2 2026, worth $1.44B in total; superinvestors Maverick Capital and Duquesne Family Office hold it.
13F holders, Q4 2023
Institutional positions in Belite Bio, Inc as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 17
- +10 vs. Q3 2023
- Shares held
- 155.1K
- +55.5K (+55.7%) vs. Q3 2023
- Total value
- $7.10M
- +$3.93M (+124.1%) vs. Q3 2023
- New holders
- 12
- 3 more added
- Sold out
- 2
- 1 more reduced
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting BLTE on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 80 | $1.44B |
| Q1 2026 | 75 | $1.42B |
| Q4 2025 | 69 | $1.15B |
| Q3 2025 | 34 | $169.3M |
| Q2 2025 | 18 | $4.51M |
| Q1 2025 | 18 | $9.91M |
| Q4 2024 | 22 | $17.8M |
| Q3 2024 | 15 | $3.69M |
| Q2 2024 | 11 | $8.52M |
| Q1 2024 | 11 | $2.23M |
| Q4 2023 | 17 | $7.10M |
| Q3 2023 | 7 | $3.17M |
| Q2 2023 | 6 | $14.9M |
| Q1 2023 | 8 | $25.4M |
| Q4 2022 | 7 | $25.9M |
| Q3 2022 | 8 | $3.87M |
| Q2 2022 | 6 | $2.15M |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Belite Bio, Inc; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Advisor Group Holdings, Inc. | 36 | $1.65K | 0.00% | +36 | New |
| GAMMA Investing LLC | 199 | $8.64K | 0.00% | +199 | New |
| UBS Group AG | 348 | $15.9K | 0.00% | −535−60.6% | Reduced |
| EntryPoint Capital, LLC | 781 | $35.7K | 0.03% | +781 | New |
| BlackRock Inc. | 1,805 | $82.6K | 0.00% | +1,805 | New |
| Virtus ETF Advisers LLC | 2,096 | $95.9K | 0.06% | +2,096 | New |
| Bank of America Corp | 2,206 | $100.9K | 0.00% | +2,143+3,401.6% | Added |
| Renaissance Technologies LLC | 4,900 | $224.0K | 0.00% | +4,900 | New |
| Jump Financial, LLC | 5,200 | $237.9K | 0.01% | +5,200 | New |
| Geode Capital Management, LLC | 6,700 | $306.5K | 0.00% | 00.0% | Unchanged |
| Point72 Asset Management, L.P. | 7,700 | $352.3K | 0.00% | +7,700 | New |
| JPMorgan Chase & Co | 14,267 | $652.7K | 0.00% | +14,267 | New |
| Marshall Wace, LLP | 16,011 | $732.5K | 0.00% | +16,011 | New |
| Cubist Systematic Strategies, LLC | 16,882 | $772.4K | 0.01% | +16,882 | New |
| State Street Corp | 17,557 | $803.2K | 0.00% | +592+3.5% | Added |
| Morgan Stanley | 22,421 | $1.03M | 0.00% | +21,983+5,018.9% | Added |
| Armistice Capital, LLC | 36,000 | $1.65M | 0.04% | +36,000 | New |
| Atria Wealth Solutions, Inc. | 0 | $0 | 0.00% | −74,019−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −525−100.0% | Sold out |